ACET
Adicet Bio Inc

3,761
Mkt Cap
$82.3M
Volume
1.29M
52W High
$1.12
52W Low
$0.4471
PE Ratio
-0.42
ACET Fundamentals
Price
$0.5629
Prev Close
$0.537
Open
$0.5475
50D MA
$0.775
Beta
0.91
Avg. Volume
1.77M
EPS (Annual)
-$1.33
P/B
0.41
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it...
Business Wire·6d ago
News Placeholder
More News
News Placeholder
Adicet Bio, Inc. (NASDAQ:ACET) Receives Consensus Rating of "Moderate Buy" from Analysts
Adicet Bio, Inc. (NASDAQ:ACET - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the seven analysts that are currently covering the stock, MarketBeat.com reports...
MarketBeat·11d ago
News Placeholder
Adicet Bio's (ACET) "Outperform" Rating Reiterated at Wedbush
Wedbush reiterated an "outperform" rating and issued a $5.00 price target on shares of Adicet Bio in a report on Thursday...
MarketBeat·27d ago
News Placeholder
Adicet Bio (NASDAQ:ACET) Releases Earnings Results, Misses Expectations By $0.03 EPS
Adicet Bio (NASDAQ:ACET - Get Free Report) issued its quarterly earnings results on Wednesday. The company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of...
MarketBeat·28d ago
News Placeholder
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it...
Business Wire·1mo ago
News Placeholder
Adicet Bio to Participate in a Fireside Chat at the Guggenheim 2nd Annual Healthcare Innovation Conference
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that...
Business Wire·1mo ago
News Placeholder
Adicet Bio Announces First Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Treatment-Refractory Rheumatoid Arthritis (RA)
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that the...
Business Wire·2mo ago
News Placeholder
Are Medical Stocks Lagging Exact Sciences (EXAS) This Year?
Here is how Exact Sciences (EXAS) and Adicet Bio, Inc. (ACET) have performed compared to their sector so far this year.
Zacks·2mo ago
News Placeholder
Adicet Bio (ACET) Upgraded to Buy: Here's What You Should Know
Adicet Bio (ACET) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks·2mo ago
News Placeholder
Adicet Bio (ACET) Upgraded to Buy: Here's Why
Adicet Bio (ACET) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks·4mo ago

Latest ACET News

View

Advertisement|Remove ads.

Advertisement|Remove ads.